BTM are useful in clinical practice as they are inexpensive and they have proven useful for treatment monitoring and identification of poor adherence. BTM cannot be used in individual patients for identifying accelerated bone loss or an increase in fracture risk or in deciding on the optimal therapy. They are useful for monitoring both anti-resorptive and anabolic treatment. Response can be defined as a result that exceeds an absolute target, or by a change greater than the least significant change; if such a response is not present, then poor compliance or secondary osteoporosis are likely causes. A baseline BTM measurement is not always made; in that case, a value of BTM on anti-resorptive treatment that is low or low normal or above the reference interval for anabolic therapy may be taken to indicate satisfactory response. We provide an approach to using these bone turnover markers in clinical practice by describing algorithms for anti-resorptive and anabolic therapy and describing the changes we observe in the clinical practice setting.
Introduction
The fractures that result from osteoporosis are a major public health problem (Eastell 2016 1 ). Osteoporosis is characterised by reduced bone mass and microarchitectural deterioration leading to increased bone fragility and may be diagnosed by measurement of bone mineral density (BMD) using dual-energy x-ray absorptiometry. A BMD value at the spine or hip that is 2.5 standard deviations or more below the average value for healthy young women is considered to represent osteoporosis, according to the WHO Working Group. Several treatments have been licensed for use in osteoporosis that are effective in reducing the risk of fracture.. This article focuses on the use of bone turnover markers (BTM) in osteoporosis. BTM can be measured in serum, plasma and urine and their levels relate to the activity of osteoblasts (bone formation markers) and osteoclasts (bone resorption markers). Bone formation markers include proteins that are specific to bone (osteocalcin), or not so specific to bone such as fragments of type I procollagen released during formation of type I collagen (N-propeptide of type I collagen, PINP) and the bone isoform of alkaline phosphatase (bone ALP). Bone resorption markers include fragments released from the telopeptide (end) region of type I collagen following its enzymatic degradation, including the N-telopeptide of type I collagen (NTX) and the C-telopeptide of type I collagen (CTX), deoxypyridinoline and the enzyme tartrate resistant acid phosphatase (Table 1) .
In women, the BTMs increase after the menopause and in other situations of accelerated bone loss. In men, there is little increase with age. In cohort studies of women (but not of men), the higher the BTM, the more rapid the bone loss and the greater the risk of fracture. Thus, the measurement of BTM may have clinical relevance to the individual.
Currently, the main clinical use for BTM is for the monitoring of response to therapy. A typical goal of therapy might be to lower BTM to values found in women before the menopause.
History, assays and validation
Bone histomorphometry is the gold standard for assessment of bone turnover, but it is invasive, cannot be repeated many times in an individual and requires specialist laboratory interpretation. Bone turnover can also be quantified with calcium balance and kinetic studies, but they are time-consuming, use radio-isotopes and again need specialist interpretation.
Therefore, for clinical use in large numbers of patients there is a need for measures that can be made on easily accessible samples (single measurements of blood or urine), inexpensively, don't require time-consuming specialist processing, and give results that can be interpreted by non-specialist health care practitioners.
The BTM that were developed initially were not bone-specific (for example, hydroxyproline and total alkaline phosphatase), the assays were technically challenging (HPLC for total deoxypyridinoline) and therefore costly and difficult to implement widely.
The newer BTM are more bone-specific and the use of enzyme-linked immunosorbent assays (ELISA) and autoanalyser techniques have made them widely available and more affordable ( Table 1) .
Although assays for total alkaline phosphatase (ALP) were available in the 1920s, only about half of the total ALP is from bone. Hydroxyproline assays were developed in the 1950s, but again were not specific for bone, and were laborious and dangerous (they resulted in explosions). There were significant developments in the 1980s and 1990s with assays for pyridinium crosslinks (deoxypyridinoline and pyridinolone), bone ALP, PINP and osteocalcin and progression from HPLC to immunoassays.
The introduction of automated immunoassay analysers in 2000 was a major technical advance. These are widely used in clinical practice for measuring many analytes, including hormones, as well as BTM and they do so with high precision (CV less than 5%) and reliability.
BTM have been validated against gold standard methods for studying bone turnover such as a comparison with tracer kinetics and bone histomorphometry, both in health (Eastell 1988 2 ) and in response to osteoporosis treatments (Eastell 1997 3 ). Currently-used BTM were evaluated in a study of 370 women with osteoporosis (Chavassieux 2015 4 ). BTM
were assessed against dynamic histomorphometry of iliac crest biopsies. There were weak to moderate correlations (highest r-value was 0.41) between the bone formation markers PINP or bone ALP and bone formation estimates, and between CTX and bone resorption estimates.
Practical aspects
There are different requirements for the use of BTM in clinical practice compared to the research setting. In clinical practice, patients may attend appointments at any time of day and there may be a delay before samples are transported to the laboratory. Patients often have complex medical problems and take multiple medications. In this context, some
properties of BTM present challenges to their clinical use.
BTM need to be measured reliably and easily, be locally accessible, inexpensive and be unaffected by the time of day the samples are obtained.
The bone resorption markers show a strong circadian rhythm and decrease shortly after feeding. Thus, it is recommended that blood samples for CTX be drawn from the patient following an overnight fast between 0730 and 1000 (Szulc 2017 5 CTX, DPD), it is usual to measure urinary creatinine and to express the result as the BTM to creatinine ratio to correct for urinary dilution.
For bone formation markers, there is a weaker circadian rhythm and so the sample can be drawn at any time of the day (Szulc 2017 5 ). Serum or plasma should be measured the same day or stored in the freezer until measured (Szulc 2017 5 ) . EDTA plasma should not be used for bone ALP measurement (Szulc 2017 5 ) . Osteocalcin is affected by haemolysis which can lead to a falsely low result. BTM, especially bone formation markers, are increased following fracture and are affected by some medical conditions and treatments, as discussed below (Szulc 2017 5 ).
Choice of BTM
It is logical to include a bone resorption and a bone formation assay when evaluating bone turnover. The choice of BTM will be determined by local availability and cost. It will also be determined by the clinical picture. Thus, in chronic kidney disease, the markers that are usually excreted by the kidney circulate at very high levels and so markers that are not excreted by the kidney are best used, e.g. Bone ALP and intact PINP. In the evaluation of glucocorticoid treatment on bone, markers that are sensitive to the bone effects of these drugs may be most useful, e.g. osteocalcin and PINP which are affected in a dose-dependent manner. These markers are not, however, useful to evaluate the effect of anti-resorptive therapy in these patients. Critical Difference' (Fraser 8 ). It is calculated as 2.77 times the coefficient of variation; the latter includes both assay and within-subject variability.
Prediction of bone loss
High bone turnover is associated with more rapid bone loss in postmenopausal women (Shieh 2016 9 ) and BTM have been studied in evaluation this relationship. Higher BTM are associated with bone loss from both trabecular and cortical bone at the hip; and also relate to greater periosteal expansion in the femoral neck (Marques 2016 10 ). The assessment is improved by making more than one BTM measurement (Ivaska 2008 11 ) . Estimation of the rate of bone loss in a postmenopausal woman when deciding about her need for antiresorptive treatment would potentially be useful. Unfortunately, the association between BTM and bone loss is not sufficient to classify individuals reliably by their BTM level (Rogers 2000 12 ).
Prediction of fracture
It would also be of interest to estimate the risk of fracture in the individual postmenopausal woman when deciding about the need for anti-resorptive treatment and high bone turnover is associated with increased risk of several types of fracture in both men and women ( ).
Selection of therapy
Intuitively, we would like to choose our therapies based on the mechanism of bone loss underlying the osteoporosis. Thus, we might use anti-resorptive therapies Similarly, the baseline BTM did not predict the fracture benefit with teriparatide (Delmas   2006   17 ). In general, a low PINP is associated with lower rates of bone loss and lower response to zoledronic acid. (Eastell 2015 18 ) Further research is needed.
Treatment used for osteoporosis
Despite having several treatments that reduce the risk of fracture in osteoporosis it is well established that adherence to these treatments can be poor, especially in the case of oral bisphosphonates for which the dosing instructions are complex. There is therefore a need to identify optimal treatment response in individual patients. It has been proposed that treatment failure may be considered if two or more fractures occur on treatment (Diez Perez 2012 19 ) based on evidence from clinical trials of drugs for osteoporosis in which there is a large reduction in risk for spine and hip fracture, although the reduction in risk of other fractures is lower. In practice, the occurrence of two or more fractures during treatment is a very rare event. Bone mineral density is commonly used as a tool to monitor treatment in the individual and an increase that exceeds the least significant change, for example an increase in lumbar spine or total hip BMD more than 4% (Diez Perez 2012 19 ) may be considered a response. However, such changes occur over many months and persistence with medication declines very early in treatment (less than 50% after 12 months,
Netelenbos 2011 . Another advantage to using BTM rather than bone mineral density is that measurements are less expensive. In our hospital setting, a PINP measurement costs less than 20% that of a bone mineral density measurement. Finally, BTM may be a better surrogate for fracture risk reduction than BMD.
The proportion of treatment effect explained by BTM has usually been higher than for BMD (Vasikaran 2011 7 ) .
Bisphosphonate
Bisphosphonates are the most commonly-used drugs for osteoporosis. There are three oral bisphosphonates that are licensed in most countries, namely alendronate, risedronate and ibandronate. The absorption of the oral bisphosphonates is very poor and as the dosing regimen is complex, many patients do not comply fully with the instructions so do not achieve an optimal response even though they may take their medication regularly. The oral bisphosphonates have been compared in the TRIO study (Clinical Trial Number: NCT00666627) (Naylor 2015 22 ) to evaluate the clinical utility of BTM to assess response.
Alendronate and ibandronate decreased BTM (CTX, NTX) more than risedronate. In this study, more than 80% of patients responded to treatment as defined by a decrease more than the LSC for CTX (56%) and PINP (38%) after 3 months of treatment. Response can also be defined as a reduction to a level below the mean found in healthy young women (Naylor 2015 22 ). In one study, the mean values were given as 217 to 317 ng/L for CTX and 32 to 38 μg/L for PINP (Morris 2017 23 ).. In the assessment of treatment response in the individual, the magnitude of the decrease has also been found to be important; for example, with alendronate (Bauer 2004 24 ) and risedronate (Eastell 2003 25 ) the greater the reduction in Zoledronic acid is given by annual intravenous infusion, thus avoiding concerns about poor absorption. It results in a reduction in CTX by 2 weeks and when it is given for 6 years as in the Horizon Study, the suppression of CTX and PINP is maintained (Black 2015 26 ). PINP was found to be even better than CTX and BMD in the Horizon study at identifying clinical (fracture) efficacy and responders (Bell 2016 27 ). As with the oral treatments, the greater the reduction in PINP with zoledronic acid, the greater the reduction in the risk of vertebral fractures (Jacques 2012 28 ).
Denosumab
Denosumab inhibits bone resorption, leading to an early and large decrease in bone resorption markers followed by a later and smaller decrease in bone formation markers.
Bone resorption markers (such as CTX) decrease within 24 hours of treatment. In the 
SERMs
Selective receptor oestrogen agonists (SERM) such as raloxifene have a weaker effect on bone turnover than bisphosphonates and denosumab. Even so, their effect can be monitored using BTM. In 60 to 65% of women with osteopenia, a significant response could be demonstrated using the LSC approach with CTX or PINP (Naylor 2016 34 ). The BTM response to raloxifene was greatest in those with greatest adherence (Finigan 2013 35 ) providing further support for use of BTM as a means of identifying poor adherence to therapy (see below).
Teriparatide
Teriparatide is an anabolic agent administered as a daily subcutaneous injection and bone formation markers increase within days of starting treatment ).
The licence for teriparatide is for 2-years as there is a concern about osteosarcoma with long-term use and the effect of the drug wanes after three years of therapy. There is accelerated bone loss after stopping teriparatide, but this can be prevented by administering bisphosphonates, raloxifene or denosumab (Ebina 2016 40 ).
Abaloparatide is a new licensed anabolic therapy for osteoporosis (Shirley 2017 41 ). It is a synthetic peptide analogue of the human parathyroid hormone-related protein and works through the PTH receptor as does teriparatide. However, the increase in PINP is less than with teriparatide (Miller 2016 42 ). The clinical utility of BTMs for monitoring abaloparatide therapy have not yet been fully reported.
Practical approach to monitoring
We have been using BTM to monitor osteoporosis therapy in our secondary care practice for 20 years. We have observed that many patients commencing treatment and having a poor BTM response are identified as having minor errors in following the dosing instructions that may not be picked up by a brief medication review. This is particularly important as most osteoporosis medication prescribing takes place in general practice by non-specialists who may not appreciate the limited absorption of oral bisphosphonates and the need for complete and consistent adherence to the dose regime. In primary care, time and resource to undertake early assessment of compliance is also limited and so we felt it appropriate to roll out the approach of monitoring osteoporosis therapy using BTM into general practice. CTX can be used in the same way as for PINP for monitoring in practice and it has the advantage of the change being earlier than for PINP (Naylor 2015 22 ). The mean CTX value is 280 ng/L (Morris 2016 23 ) and the least significant change value is about 100 ng/L (in Table 2 it is 60 to 80 ng/L depending on the method).
The estimates of least significant change (and the geometric means) are based on the assay and within-subject variability and so are a statistical approach and can be used for the monitoring of any intervention on bone turnover. 
Treatment targets
The rationale for choosing a least significant change of 10 μg/L is that changes up to this level could occur by chance in up to 95% of people whereas a change greater than this is relatively uncommon and it is based on untreated postmenopausal women with low bone mineral density (Eastell 2006 45 ). The least significant change is also similar for both the Roche Cobas and the IDS iSYS assays as too is the mean response to oral bisphosphonates ( Table 2 ).
The rationale for choosing a target PINP value of <35 μg/L is that in clinical trials of anti- Table 2 that the mean values for young women are similar for PINP and close to 35 μg/L for both assays. It can also be seen that the least significant change is similar and as the baseline PINP was around 46 μg/L, an LSC of 23% equivalent to about 10 μg/L. It is also notable that the mean reduction on treatment after 12 to 13 weeks is very similar. The attraction of using PINP rather than CTX can be seen from this table -the LSC is lower for PINP than CTX and PINP does not need to be taken in the fasting state.
The concepts of least significant change and target for treatment are not unique to the use of bone turnover markers in osteoporosis and so are already familiar to colleagues in primary care. In type 2 diabetes, it is usual to monitor with haemoglobin A 1c and consider the reference change value (the same as least significant change) and the target; the critical values used are 0.5% change and a target of 7.0% (Little 2011   48 ).
Sources of variability in BTMs
Many clinical factors influence BTM measurements but we pay particular attention to the occurrence of a fracture or to treatment with glucocorticoids as these are common confounders and have a clinically important impact. There is a large increase in PINP after a fracture, with a mean increase of 55% six weeks after wrist fracture (Ingle 1999 49 ), 96% six weeks after ankle fracture (Ingle 1999 50 ) and 100% 12 weeks after tibial shaft fracture 
Evaluation of use in clinical practice

Antiresorptive Therapy
We introduced the monitoring algorithm ( Figure 1 ) into primary care in Sheffield in September 2011 and conducted an audit on all patients being evaluated for osteoporosis at the Metabolic Bone Centre in Sheffield in July 2012. New treatment was recommended to the general practitioner in 108 cases (mean age 65 years, 86% female) and baseline PINP was obtained by the GP in 76 of these. Follow-up measurement was made in 34 of these.
We found that at follow-up, 27 (79%) met the criteria for treatment response (Figure 2 ).
Among the 7 people with poor response, we found reasons for this in 3 cases (poor compliance, intercurrent surgery and the sample measured too early). We were encouraged by this early uptake of PINP monitoring and are working further to develop awareness among general practitioners and to develop confidence in its use.
We acknowledge that monitoring using PINP in clinical practice is by necessity pragmatic, needing to minimise cost and patient inconvenience and differs considerably from the research approach. Nonetheless, the approach has been welcomed by GP colleagues and we believe is preferable to no monitoring or reassessment of BMD after 2 years, by which time a high proportion of patients have stopped treatment.
The interpretation of PINP results and the need to change treatment needs to be considered on an individual basis using clinical judgement and considering factors such as the severity of the osteoporosis, likelihood of poor compliance (e.g. presence of dementia) and presence of known confounders.
In all patients with suboptimal response, especially if repeat PINP remains increased, change in treatment needs to be considered. We would often move onto parenteral treatment at this point to eliminate problems due to poor compliance and/or poor absorption.
Our initial evaluation of the use of PINP for monitoring anti-resorptive therapy in clinical practice ( Figure 2 ) drew our attention to several types of responses.
Black -a significant decrease to below 35µg/L This is consistent with a good response to a level that is associated with low fracture risk and so is the optimal response. We would recommend the physician confirms compliance, enquires about any drug side-effects and encourages the patient to continue therapy and report any new issues. Medications should be reviewed at least annually and risk assessment including DXA planned at 5 years. Further PINP measurement is not considered necessary unless the clinical situation alters. 
Monitoring offset of effect in the individual
It is often recommended that oral bisphosphonate therapy is stopped after 5 years in milder forms of osteoporosis (Adler 2016 55 ) . The rationale for this is that longer-term therapy may increase the risk of atypical femur fractures and once treatment is stopped there is continued benefit with little bone loss from the spine and continued (if mild) suppression of bone turnover (Black 2006 56 ). Attempts have been made to monitor the offset of effect with BMD, but the changes at the hip are quite small relative to the least significant change and so only a small proportion of patients are identified as having offset of effect, with just 29%
having more than 5% bone loss from the total hip 5 years after stopping alendronate (McNabb 2013   57 ). BTM could be used for this purpose, perhaps using the LSC approach to examine for an increase or the threshold approach to identify a value that is above the mean for young women and so merits re-starting therapy. There has been little published on this topic and there appears to be little association between change in BMD or BTM and fracture risk off treatment with alendronate (Bauer 2014 58 ). We await further research before making any recommendations.
Anabolic Therapy
We also use PINP to assess response to teriparatide treatment. Teriparatide is used in patients with severe and complicated osteoporosis so it is important to consider if response is optimal as early as possible, particularly as treatment is limited to 24 months. Suboptimal response may be due to issues with compliance, drug storage or injection technique.
We evaluated 91 patients monitored using PINP. All had previously been treated with anti-resorptive therapy, mean age 71 years (89% female). The baseline PINP was 35 μg/L using the Roche Cobas automated immunoassay analyser, reflecting the effect of the prior anti-resorptive treatment. We took our treatment targets as an increase of more than the least significant change in PINP at months one and three (10 μg/L) (Eastell 2006 45 ) and an increase to above the reference interval of 69 μg/L (Glover 2008 59 ) on at least one occasion.
We found that by 3 months of treatment 93% exceeded the least significant change and 66%
exceeded the upper limit of the reference interval ( Figure 4 and change in lumbar spine BMD at two years but this was difficult to evaluate as only 29% of our patients had reliable spine scans due to very high prevalence of vertebral fracture and degenerative change. The baseline PINP in this evaluation were low as all patients had previously been treated with anti-resorptive drugs and so these findings not relevant to patients starting teriparatide with no such prior therapy.
In our experience, treatment is often commenced without measurement of a baseline PINP, especially in primary care. In this situation, it is particularly important to undertake a thorough evaluation of adherence to treatment and we find it remains valuable to make the 6 month measurement. A PINP value on treatment that is low or low normal for antiresorptive treatment (ie <35 µg/L) or above the reference interval for anabolic therapy (ie >69 µg/L) may be presumed to indicate adequate response. However, this approach is less well documented than the least significant change approach.
Current recommendations: Examples
The 
